Clinical Trials Browser

Withdrawn × sargramostim × Clear all

NCT05284214 2023-09-15

SALIENT

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT04703426 2023-05-22

Sargramostim (GM-CSF) + PD-1

Phase 2 Withdrawn

Melanoma

NCT00006669 2021-10-27

Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

Phase 2 Withdrawn

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT01826864 2020-07-27

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Phase 3 Withdrawn

Melanoma

NCT00621036 2018-11-26

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Phase 2 Withdrawn

CNSDermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Central Nervous System Neoplasms, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT03282188 2018-05-04

REO13 Melanoma With of Without GM-CSF

Phase 1/2 Withdrawn

Melanoma, Skin Neoplasms

NCT00002664 2017-07-13

Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02520102 2017-04-20

Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02470559 2016-02-17

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Phase 1 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01530984 2015-10-05

Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT00446173 2015-08-25

Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00176280 2015-06-18

Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma

Phase 2 Withdrawn

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT00022230 2015-05-05

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT00085579 2012-12-12

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Phase 2 Withdrawn

Melanoma